key: cord-0964855-cvbxv7h7
authors: Stamatatos, Leonidas; Czartoski, Julie; Wan, Yu-Hsin; Homad, Leah J.; Rubin, Vanessa; Glantz, Hayley; Neradilek, Moni; Seydoux, Emilie; Jennewein, Madeleine F.; MacCamy, Anna J.; Feng, Junli; Mize, Gregory; De Rosa, Stephen C.; Finzi, Andrés; Lemos, Maria P.; Cohen, Kristen W.; Moodie, Zoe; McElrath, M. Juliana; McGuire, Andrew T.
title: A single mRNA immunization boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
date: 2021-03-10
journal: medRxiv
DOI: 10.1101/2021.02.05.21251182
sha: 0204876e079d897b6de78d76c55fa14c9b0b7971
doc_id: 964855
cord_uid: cvbxv7h7

Emerging SARS-CoV-2 variants have raised concerns about resistance to neutralizing antibodies elicited by previous infection or vaccination. We examined whether sera from recovered and naive donors collected prior to, and following immunizations with existing mRNA vaccines, could neutralize the Wuhan-Hu-1 and B.1.351 variants. Pre-vaccination sera from recovered donors neutralized Wuhan-Hu-1 and sporadically neutralized B.1.351, but a single immunization boosted neutralizing titers against all variants and SARS-CoV-1 by up to 1000-fold. Neutralization was due to antibodies targeting the receptor binding domain and was not boosted by a second immunization. Immunization of naïve donors also elicited cross-neutralizing responses, but at lower titers. Our study highlights the importance of vaccinating both uninfected and previously infected persons to elicit cross-variant neutralizing antibodies.

The SARS-CoV-2 betacoronavirus first emerged in the Hubei Province of China in late 2019 and has since infected over 115 million people and caused over 2.5 million deaths in 192 countries (1-3).

Infection is mediated by the viral spike protein (S) which is comprised of an S1 domain that contains a N-terminal domain (NTD), a C-terminal domain (CTD), and a receptor binding domain (RBD) which mediates attachment to the entry receptor angiotensin converting enzyme 2 (ACE2), and an S2 domain that contains the fusion machinery (4) (5) (6) (7) (8) .

Pre-existing immunity to SARS-CoV-2 is associated with protection against re-infection in humans (9) (10) (11) and in non-human primates (12, 13) . Although the correlates of protection in humans against repeat infection or following vaccination have not been firmly established, neutralizing antibodies (nAbs) are thought to be an important component of a protective immune response against SARS-CoV-2 (14, 15) . In support of this, passive transfer of nAbs limits respiratory tract infection and protects against infection in animal models (16) (17) (18) (19) (20) and may contribute to protection against infection in humans (9) . SARS-CoV-2 infection rapidly elicits nAbs (16, (21) (22) (23) (24) that decline, but remain detectable over several months (25) (26) (27) (28) (29) .

The majority of serum neutralizing antibody responses elicited during natural infection are directed at the receptor bidning domain (RBD) (21, 23, 30, 31) . Numerous neutralizing anti-RBD monoclonal antibodies (mAbs) have been characterized, the most potent of which block the RBD-ACE2 interaction (16, 17, (22) (23) (24) (32) (33) (34) (35) (36) (37) . Neutralizing against other region of the viral spike have also been identified (24, 33, (38) (39) (40) (41) (42) .

Two mRNA-based vaccines (Pfizer/BioNTech BNT162b2, and Moderna mRNA-1273) have received emergency use authorization in several countries. Both encode a stabilized ectodomain version of the S protein derived from the Wuhan-Hu-1 variant isolated in December 2019 (43) , show greater than 94% efficacy at preventing COVID-19 illness (44) (45) (46) (47) , and elicit nAbs (48, 49) .

Due to the high global burden of SARS-CoV-2 transmission, viral evolution is occurring. Recently, viral variants of concern have emerged in the United Kingdom (B.1.1.7), South Africa (B.1.351), and Brazil (P.1) that harbor specific mutations in their S proteins that may be associated with increased transmissibility (50) (51) (52) (53) (54) (55) .

Of particular concern are mutations found in the B.1.351 lineage, which is defined by the D80A and D215G in the N-terminal domain (NTD), and the K417N, E484K, N501Y mutations in the RBD and the D614G mutation in S2 (52, 56) . An A701V mutation in S2 is also observed at high frequencies, while deletions in 242-244 and a R246I mutation in the NTD and a mutation in the leader peptide (L18F) are present at lower frequencies (52) .

The B.1.1.7, B.1.351, and P.1 lineages all harbor a N501Y mutation in the RBD which increases the affinity for the ACE2 receptor (57, 58) , and a D614G mutation which increases virion spike density, infectivity and transmissibility (59, 60) . The B.1.351 and P.1 lineages also share the E484K mutations in the RBD and both variants are mutated at 417 (K417T in P.1).

Mutations found in emergent S variants decrease sensitivity to neutralization by mAbs, convalescent plasma, and sera from vaccinated individuals (27, 37, 58, (61) (62) (63) (64) (65) (66) (67) (68) (69) (70) . As a result, there is concern that these and other emerging variants can evade neutralizing antibody responses generated during infection with variants circulating earlier in the pandemic and also from . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 10, 2021. ; https://doi.org/10.1101/2021.02.05.21251182 doi: medRxiv preprint neutralizing antibody responses elicited by vaccines based on the spike protein of the Wuhan-Hu-1 variant. Indeed, there is concern that these mutations are responsible for reduced efficacy observed in ongoing trials of SARS-CoV-2 vaccines in South Africa (71, 72) .

Here, we evaluated the neutralization susceptibility of spike variants harboring lineagedefining and prevalent B.1.351 mutations to sera from 15 donors with previously confirmed SARS-CoV-2 infection (herein referred to as previously infected donors or PIDs), that were collected prior to, and following one or two immunizations with either mRNA vaccine, or from 13 uninfected donors who received two doses of the above vaccines (herein called naïve donors or NDs; Tables S1 and S2), as well as anti-spike mAbs isolated from infected but not vaccinated patients.

Antibody neutralization experiments were performed with pseudoviruses expressing either the full-length Wuhan-Hu-1 S, or either of two versions of the B.1.351 lineage S, one herein referred to as B.1.351 containing the lineage-defining S mutations D80A, D215G, K417N, E484K, N501Y and D614G mutations and the A701V mutation that is highly prevalent in this lineage, and a second variant that also includes a Δ 242-243 deletion (B.1.351Δ242-243).

The viral stocks were appropriately diluted to achieve comparable entry levels during the neutralization experiments (Fig. S1 ).

We first evaluated the neutralizing potency of several mAbs isolated from non-vaccinated patients infected early in the pandemic, which target different epitopes: three against the RBD (CV30, CV3-1 and CV2-75) and one against the NTD (CV1) (Fig. S2 ). CV30 is a member of the VH3-53 class of antibodies that bind to the receptor binding motif (RBM) (22, 32, (73) (74) (75) (76) (77) (78) . It makes direct contact with the K417 and N501 residues in the RBM that are mutated in the B.1.351 and P.1 lineages, but unlike other known VH3-53 mAbs it does not contact E484 (78) .

The neutralization potency of this mAb was ~10-fold weaker towards both B.1.351 variants (Fig.   1A) . Similarly, the non-VH3-53 mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants (Fig. 1B) , while CV2-75 was modestly less effective (Fig. 1C ). In contrast, the anti-NTD CV1 mAb was unable to neutralize either B.1.351 variant (Fig. 1D ). As expected, the control anti-EBV mAb AMMO1 was non-neutralizing (79) (Fig. 1E) (Table S1 ) after the first and second immunizations in the PIDs, and 6-28 days after the second immunization in the NDs. Three PIDs experienced asymptomatic SARS-CoV-2 infection (donors D, L, and M; Table S1 ) two of whom, L and M, did not have detectable anti-RBD IgG antibodies prior to immunization, while the third, D, had low but detectable serum anti-RBD IgG antibody titers ( Fig. 2A ). In the 13 PIDs with RBD-specific IgG antibodies prior to vaccination, a single dose of either vaccine boosted these titers by ~500-fold ( Fig. 2A) . Across all PIDs there was a 200-fold increase in median RBD-specific IgA titers post-vaccination (Fig. 2B) . Overall, in PIDs, a single vaccine dose elicited 4.5-fold higher IgG, and 7.7-fold higher IgA titers than two vaccinations in NDs. RBD-specific IgM titers were generally lower and were not significantly boosted in response to vaccination in both PIDs and NDs (Fig. 2C) . In PIDs, a concomitant increase in RBD- (Fig. 2D ) and S-specific IgG + (Fig. 2E ) memory B cell frequencies took place after vaccination. The two PIDs that lacked RBD-specific IgG titers prior . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 10, 2021. ; https://doi.org/10.1101/2021.02.05.21251182 doi: medRxiv preprint to immunization (donors L and M) also lacked RBD-specific IgG+ memory B cells (Fig. 2D) and had lower frequencies of S-specific IgG + memory B cells after vaccination. Consistent with the serology data, an increase in the frequency of IgA + (Fig. 2F ) but not IgM + spike-specific memory B cells was observed (Fig. S3 ). Vaccination also induced S-specific CD4 + T-cell responses (Fig. 2G ).

Sera from 12 of 15 PIDs sampled before vaccination neutralized the Wuhan-Hu-1 SARS-CoV-2 variant ( Fig. 3A and S4 ). The non-neutralizing sera were from the three asymptomatic PIDs who had low or undetectable anti-RBD IgG titers ( Fig. 3A dashed lines and Fig. S4 ), while pre-vaccine sera from the NDs were also non-neutralizing (Fig. S5) . Consistent with the observed increase in binding antibodies following a single immunization in PIDs with preexisting RBD-specific IgG titers, the median half-maximal neutralizing titers (ID 50 ) were boosted approximately 1000-fold after the first dose, while the second dose had no effect (Fig. 3A ). In the two PIDs lacking RBD-specific IgG titers prior to vaccination, the first vaccine dose elicited lower neutralizing titers (ID 50 = ~100 in donor L and ~1,100 in donor M; Fig. 3A ). In the NDs, two doses of the vaccine elicited ID 50 titers that were ~10-and 5-fold lower than those elicited by one or two doses in the PIDs, respectively ( Fig. 3A and S6 ). Collectively, these data indicate that in PIDs who generate adequate immunological memory to the RBD, a single vaccine dose elicits an anamnestic response resulting in RBD-binding and neutralizing antibody responses that are superior to a two-dose regimen in uninfected donors.

We next evaluated the ability of sera collected before and after immunization in NDs and PIDs to neutralize the more resistant B.1.351 and B.1.351-Δ242-243 pseudoviruses. These variants are 0.5% and 0.7% divergent from the Wuhan-Hu-1 variant. We also included SARS-CoV-1 pseudoviruses in this analysis, as a representative variant that is even more dissimilar to . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 10, 2021. ; https://doi.org/10.1101/2021.02.05.21251182 doi: medRxiv preprint the vaccine. SARS-CoV-1 and SARS-CoV-2 are 24%, 26% and 50% divergent in the overall S protein, RBD and receptor binding motif, respectively (80) . As a consequence, several mAbs that potently neutralize SARS CoV-2 fail to bind SARS-CoV-1 (16, (22) (23) (24) . . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 10, 2021. ; https://doi.org/10.1101/2021.02.05.21251182 doi: medRxiv preprint vaccinated NDs were able to achieve 80% neutralization of B.1.351-Δ242-243, and none could achieve 80% neutralization of SARS-CoV-1 (Fig. S7B ).

The B.1.351 and B.1.351-Δ242-243 variants contain three RBD mutations that affect the neutralization potency of anti-RBD mAbs (Fig. 1) . Moreover, pre-existing anti-RBD IgG memory appears to be important for a robust recall response to vaccination. To determine the relative contribution of anti-RBD antibodies to serum neutralization, we depleted RBD-specific antibodies from the sera of ten PIDs following one vaccination and from nine NDs after two vaccinations. This approach efficiently removed RBD-specific ( Similarly, sera from PIDs who experienced symptomatic SARS-CoV-2 infection and who had detectable anti-RBD IgG titers prior to vaccination displayed generally weak nAb titers against Wuhan-Hu-1 at one to nine months post-infection and lower, or non-existent titers against the B.1.351 variants, in agreement with another report (69) . However, provided RBDspecific IgG + memory B-cell and antibody responses were generated during infection, a single immunization with either mRNA vaccine elicited a robust recall response that boosted the autologous neutralizing titers by approximately 1000-fold and importantly, these antibody . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 10, 2021. ; https://doi.org/10.1101/2021.02.05.21251182 doi: medRxiv preprint responses cross-neutralized the B.1.351 variants, but at lower titers. In the majority of previously infected vaccinees, the anti-B.1.351-Δ242-243 neutralizing titers were comparable to those against the vaccine-matched Wuhan-Hu-1 in uninfected vaccinees. This is notable as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49) .

Moreover, vaccine-elicited antibody responses also neutralized SARS-CoV-1, but with much lower potencies. Collectively, our data suggest that the two mRNA vaccines that are based on the Wuhan-Hu-1 variant can elicit and/or boost neutralizing antibody responses, but that their potency is reduced against divergent variants.

Here, we show that the cross-neutralizing antibody responses generated after immunization in previously infected subjects are due to anti-RBD antibodies. Combined with the observation that the vaccines elicited neutralizing antibody responses that are less potent against the B.1.351 variant with the 242-243 deletion in the NTD suggests that NTD mutations can modulate the sensitivity of emerging variants to anti-RBD neutralizing antibodies. In contrast, the NTD region itself, which appears to tolerate antigenic variation in SARS-CoV-2 and other coronaviruses (50, 52, 55, 83) , does not appear to be the target of cross-neutralizing antibodies elicited by infection or vaccination. We note that there are other less-frequent mutations associated with this lineage, such as L18F, Δ 244, L244H, and R246I that were not examined here which may further increase resistance to vaccine-elicited antibodies.

Although the correlates of protection for SARS CoV-2 vaccines have not been established, studies in non-human primates indicate that even low titers of neutralizing antibodies are sufficient to prevent experimental SARS-CoV-2 infection, particularly if CD8+ Tcell responses are mounted (18) . Our study suggests that most previously infected subjects will benefit from a single immunization with either the Pfizer/BioNTech or Moderna vaccines as it . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 10, 2021. ; https://doi.org/10.1101/2021.02.05.21251182 doi: medRxiv preprint will lead to significant increases in serum neutralizing antibody responses against vaccinematched and emerging variants. The observation that a second dose administered three to four weeks following the first in previously infected donors who have clear evidence of RBD-directed immunological memory prior to vaccination did not further boost neutralizing titers, suggests that the second dose of an mRNA vaccine could be delayed in some persons who have previously been infected with SARS-CoV-2. Longitudinal monitoring of the neutralizing antibody titers before and following the first dose should be used to determine the necessity, or optimal timing of the second dose in the context of previous infection.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Frequency of Wuhan-Hu-1 RBD-specific IgG+ memory B cells (live, IgD -, CD19 + , CD20 + , CD3 -, CD14, CD56 -, singlet, lymphocytes) in PBMC from previously infected donors was measured before and after one or two immunizations. The frequency of S6P-specific IgG + (E) and IgA + (F) memory B cells in PBMC previously infected donors were measured before and after one or two immunizations. The frequency of memory B cells from uninfected donors following two vaccine doses are shown for comparison in D-F (gray dots). (G) The frequency of S-specific CD4+ T cells expressing IFN-γ and/or IL-2 and/or CD40L in PBMC from previously infected donors was measured before and after one or two immunizations. The frequency of Sspecific CD4+ T cells in PBMC from uninfected donors following two vaccine doses are shown for comparison (gray dots). Experiments were performed once. Significant differences in . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 10, 2021. ; https://doi.org/10.1101/2021.02.05.21251182 doi: medRxiv preprint infected donors before or after vaccination (A-D) or between pseudoviruses (E) were determined using a Wilcoxon signed rank test (*p<0.05, ** p<0.01 and ***p<0.001). Significant differences between previously infected and uninfected donors (A-D) were determined using a Wilcoxon rank sum test (*p<0.05, **p<0.01 and **p<0.001).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 10, 2021. ;  (ID 50 ) of (A) Wuhan-Hu-1, (B) B.1.351, (C) B.1.351Δ242-243, and (D) SARS-CoV-1 pseudoviruses was measured in recovered COVID-19 donors prior to and following a one or two immunizations with the Pfizer/BioNTech or Moderna vaccines, and in uninfected donors following two vaccine doses as indicated. Data points between previously infected donors who were symptomatic and asymptomatic are connected by solid and dashed lines, respectively in A-D. (E) Serum dilution resulting in 50% neutralization (ID 50 ) from recovered donors prior to (squares) and following a single immunization (circles) with the Pfizer/BioNTech or Moderna vaccines against Wuhan-Hu-1, B.1.351, B.1.351Δ242-243 and SARS-CoV-1 pseudoviruses as indicated. Previoulsy infected donors who were asymptomatic, negative for anti-IgG RBD antibodies, and RBD-specific IgG+ memory B cells prior to vaccination are shown as open circles. (F) Neutralizing potency (ID 50 ) of serum from uninfected donors following two immunizations with the Pfizer/BioNTech or Moderna vaccines against the indicated pseudoviruses. Each data point represents a different donor and the horizonal bars represent the medians in E and F. The dashed lines demarcate the lowest serum dilutions tested. Experiments were performed once. Significant differences in infected donors before or after vaccination, or from the same timepoint against different variants (*p<0.05, ** p<0.01 and ***p<0.001) were determined using a Wilcoxon signed rank test. Significant differences between previously infected and uninfected donors (*p<0.05, **p<0.01 and ***p<0.001) were determiend using a Wilcoxon rank sum test.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 10, 2021. ; RBD-binding antibodies were adsorbed from sera from previously infected donors after receiving a single vaccine dose, or from uninfected donors after receiving two vaccine doses using Wuhan-Hu-1 RBD immobilized to magnetic beads. Antibody binding in undepleted or RBD-depleted serum from previously infected donors was measured to RBD at a 1:500 dilution (A), and S2P at a 1:4500 dilution (B) by ELISA as indicated. (C) The serum dilution resulting in 50% neutralization (ID 50 ) of the Wuhan-Hu-1 pseudovirus was measured in undepleted or RBDdepleted of serum from the previously SARS-CoV-2 infected donors in A and B. Antibody binding in undepleted and RBD-depleted and sera from uninfected vaccinated donors was measured to RBD at a 1:500 dilution (D), and S2P at a 1:500 dilution (E) by ELISA. (F) The percent neutralization of a 1:120 dilution of undepleted or RBD-depleted of serum from the donors in D and E was measured against the Wuhan-Hu-1 pseudovirus. Experiments were performed once.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 10, 2021. ; https://doi.org/10.1101/2021.02.05.21251182 doi: medRxiv preprint

Peripheral blood mononuclear cells (PBMCs) and serum were collected from participants enrolled in the longitudinal study, "Seattle COVID-19 Cohort Study to Evaluate Immune Responses in Persons at Risk and with SARS-CoV-2 Infection". Eligibility criteria included adults in the greater Seattle area at risk for SARS-CoV2 infection or those diagnosed with COVID-19 by a SARS CoV-2 PCR assay University of Washington multiplex PCR reaction using CDC approved primers/probes for the virus nucleocapsid (N) gene, N1 and N2) or blood antibody test (SARS CoV-2 IgG Architect, Abbot). Fifteen participants who recovered from SARS-CoV-2 and 13 that were SARS-CoV2 negative were selected from among those that were the first to receive two doses of an Emergency Use Authorization COVID-19 vaccine. Samples were selected based on availability. Sample sizes, randomization, or blinding were not predetermined, nor were there specific inclusion/exclusion criteria. Serum or plasma from prepandemic controls were blindly selected at random from the study, "Establishing Immunologic Assays for Determining HIV-1 Prevention and Control", with no considerations made for age, or sex. Both studies were recruited at the Seattle Vaccine Trials Unit (Seattle, Washington, USA).

Center Institutional Review Board approved the studies and procedures (IR10440 and IR5567).

Study data were collected and managed using REDCap electronic data capture tools hosted at Fred Hutchinson Cancer Research Center (84, 85) .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 10, 2021. ; https://doi.org/10.1101/2021.02.05.21251182 doi: medRxiv preprint All cell lines were incubated at 37°C in the presence of 5% CO2. 293-6E (human female, RRID:CVCL_HF20) and 293T cells (human female, RRID:CVCL_0063) cells were maintained in Freestyle 293 media with gentle shaking. HEK-293T-hACE2 (human female, BEI Resources Cat# NR-52511) were maintained in DMEM containing 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin (cDMEM).

A stabilized version of the recombinant SARS-CoV-2 spike protein (S2P) and the SARS CoV-2 RBD were produced in 293E cells as previously described (8, 22) . Recombinant CV1, CV30 and AMMO1 were expressed in 293 cells and purified using protein A resin as previously described (22, 79) . is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 10, 2021. ; https://doi.org/10.1101/2021.02.05.21251182 doi: medRxiv preprint Percent neutralization for each well was calculated as the RLU of the average of the cells + virus wells, minus test wells (cells +mAb/sera + virus), and dividing this result difference by the average RLU between virus control (cells + virus) and average RLU between wells containing cells alone, multiplied by 100. The antibody concentration, or serum dilution that neutralized 50% or 80% of infectivity (IC 50 and IC 80 for mAbs, ID 50 and ID 80 for serum) was interpolated from the neutralization curves determined using the log(inhibitor) vs. response --Variable slope (four parameters) fit using automatic outlier detection in Graphpad Prism Software. Serum that did not achieve 50% neutralization at the lowest dilution tested (1:20) were considered negative and assigned an ID 50 value of 10.

Half-well area plates (Greiner) were coated with purified RBD protein at 16.25ng/well in PBS (Gibco) for 14-24h at room temperature. After 4 150ul washes with 1X PBS, 0.02% Tween-2 (Sigma) using the BioTek ELx405 plate washer, the IgA and IgG plates were blocked at 37°C for 1-2 hours with 1X PBS, 10% non-fat milk (Lab Scientific), 0.02% Tween-20 (Sigma); IgM plates were blocked with 1X PBS, 10% non-fat milk, 0.05% Tween-20.

Serum samples were heat inactivated by incubating at 56°C for 30 minutes, then centrifuged at 10,000 x g / 5 minutes, and stored at 4°C previous to use in the assay. For IgG ELISAs, serum was diluted into blocking buffer in 7-12 1:4 serial dilutions stating at 1:50. For IgM and IgA ELISAs, serum was diluted into 7 1:4 serial dilutions stating at 1:12.5 to account for their lower concentration. A qualified pre-pandemic sample (negative control) and a standardized mix of seropositive serums (positive control) was run in each plate and using to define passing criteria . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 10, 2021. ; https://doi.org/10.1101/2021.02.05.21251182 doi: medRxiv preprint for each plate. All controls and test serums at multiple dilutions were plated in duplicate and incubated at 37°C for 1 hour, followed by 4 washes in the automated washer. 8 wells in each plate did not receive any serum and served as blocking controls.

Plates then were plated with secondary antibodies (all from Jackson ImmunoResearch) OD 450nm measurements for each dilution of each sample were used to extrapolate endpoint titers when CVs were less than 20%. Using Excel, endpoint titers were determined by calculating the point in the curve at which the dilution of the sample surpassed that of 5 times the average OD 450nm of blocking controls + 1 standard deviation of blocking controls.

SARS-CoV-2 RBD was coupled to Pierce NHS-activated magnetic beads (Thermo Fisher) at a ratio of 50 µg of RBD to 1 mg of beads according to manufacturer's instructions and stored in PBS. Plasma samples were diluted 1:50 in DMEM in a total volume of 500µl. Diluted plasma was incubated with of 65 ul of RBD-coupled beads. Samples were continually mixed at RT for 1 hour. Diluted sera was removed from immobilized magnetic beads using a magnetic stand and the sera were incubated with fresh beads two additional times. Depleted serum was filter . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 10, 2021. ;  Flow cytometry was used to examine SARS-CoV-2-specific CD4+ T-cell responses using a validated ICS assay. The assay was similar to published reports (88, 89) and the details of the staining panel are included in Supplemental Table 4 . Two peptide pools (15 amino acids overlapping by 11 amino acids, provided by BioSynthesis) covering the spike protein of SARS-CoV-2 were used for the six-hour stimulation. Peptide pools were used at a final concentration of 1 µg/ml for each peptide. As a negative control, cells were not stimulated, only the peptide diluent (DMSO) was included. As a positive control, cells were stimulated with a polyclonal stimulant, staphylococcal enterotoxin B (SEB). Cells expressing IFN-γ and/or IL-2 and/or CD154 was the primary endpoint for antigen-specific CD4 + T cells. The overall response to spike was defined as the sum of the background-subtracted responses to the spike 1 and spike 2 individual pools. The total number of CD4 + T cells must have exceeded 10,000 the assay data to be included in the analysis.

BLI experiments were performed on an Octet Red instrument at 30°C with shaking at 500-1000 rpm. mAbs were loaded at a concentration of 20 mg/mL in PBS onto Anti-Human IgG Fc capture (AHC) biosensors (Fortebio) for 300s, followed by a 60s baseline in KB buffer (1X PBS, 0.01% Tween 20, 0.01% BSA, and 0.005% NaN 3 , pH 7.4). Probes were then dipped in KB containing either; SARS-CoV-2 RBD (2.0µM), S-2P (0.5µM), S1 NTD (0.5µM, SinoBiological Cat # 40591-V49H) or S2 (0.5µM, SinoBiological Cat # 40590-V08B) for a 300s association phase, followed by a 300s dissociation phase in KB. The binding of mature VRC01 (90) was used as negative control to subtract background binding at each timepoint.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 10, 2021. ;

H. Horton et al., Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. Journal of immunological methods 323, 39-54 (2007 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 10, 2021. ; https://doi.org/10.1101/2021.02.05.21251182 doi: medRxiv preprint ACKNOWLEDGMENTS This work was supported by generous donations to Fred Hutch COVID-19 Research Fund, and to MJM from the Paul G. Allen Family Foundation, the Joel D. Meyers Endowed Chair, and NIAID UM1 AI068618-14S1, 2UM1 AI069481-15, and UM1A057266-S1. We thank the study participants for their dedication to this project, Trevor Bedford for assistance with the selection of spike mutations to include, Laura Richert Spuhler for assistance with figure preparation, Todd

Haight and the Seattle Vaccine Unit specimen processing lab and staff for their service, and. L.S. 

Figs. S1 to S8 Tables S1 to S4

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 10, 2021. ; https://doi.org/10.1101/2021.02.05.21251182 doi: medRxiv preprint

An interactive web-based dashboard to track COVID-19 in real time

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A Novel Coronavirus from Patients with Pneumonia in China

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate

COVID-19 Outbreak at an Overnight Summer School Retreat -Wisconsin

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques

COVID-19 and the Path to Immunity

Developing a SARS-CoV-2 Vaccine at Warp Speed

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Potently neutralizing and protective human antibodies against SARS-CoV-2

Correlates of protection against SARS-CoV-2 in rhesus macaques

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients

Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19

Evolution of antibody immunity to SARS-CoV-2

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

The receptor binding domain of SARS-CoV-2 spike is the key target of neutralizing antibody in human polyclonal sera. bioRxiv

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. bioRxiv

Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-Terminal Domain Target a Single Supersite. bioRxiv

Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. bioRxiv

Isolation of cross-reactive monoclonal antibodies against divergent human coronaviruses that delineate a conserved and vulnerable site on the spike protein. bioRxiv

A new coronavirus associated with human respiratory disease in China

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates. bioRxiv

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. medRxiv

Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv

Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England. medRxiv

Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence

Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings

Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2

An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants. bioRxiv

Prospective mapping of viral mutations that escape antibodies used to treat COVID-19

SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity

SARS-CoV-2 spike D614G change enhances replication and transmission

Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. bioRxiv

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity. bioRxiv

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization. bioRxiv

Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike. bioRxiv

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines. bioRxiv

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial

Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial

Structural basis of a shared antibody response to SARS-CoV-2

An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy

Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation

An Antibody Targeting the Fusion Machinery Neutralizes Dual-Tropic Infection and Defines a Site of Vulnerability on Epstein-Barr Virus

Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine -Preliminary Report

Evidence for adaptive evolution in the receptor-binding domain of seasonal coronaviruses OC43 and 229E

Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support

The REDCap consortium: Building an international community of software platform partners

Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

OMIP-056: Evaluation of Human Conventional T Cells, Donor-Unrestricted T Cells, and NK Cells Including Memory Phenotype by Intracellular Cytokine Staining